Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice

PLoS ONE

Volumn 5, Issue 8, 2010, Pages

  Huang, Ming His ^a   Lin, Su Chen ^a   Hsiao, Chia Hsin ^a   Chao, Hsin Ju ^a   Yang, Hung Ren ^a   Liao, Chien Chun ^a   Chuang, Po Wei ^a   Wu, Huang Pi ^a   Huang, Chiung Yi ^a   Leng, Chih Hsiang ^a   Liu, Shih Jen ^a   Chen, Hsin Wei ^a   Chou, Ai Hsiang ^a   Hu, Alan Yung Chih ^a   Chong, Pele ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CPG OLIGODEOXYNUCLEOTIDE; CYTOSINE; GUANOSINE; HEMAGGLUTININ; INACTIVATED VIRUS VACCINE; INFLUENZA VIRUS A H5N1 VACCINE; NANOPARTICLE; OIL; POLYMER; SORBITAN TRIOLEATE; SQUALENE; UNCLASSIFIED DRUG; WATER; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; OLIGODEOXYRIBONUCLEOTIDE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; DRUG ADSORPTION; DRUG DELIVERY SYSTEM; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA VIRUS A H5N1; MOUSE; NANOEMULSION; NONHUMAN; PROTEIN MOTIF; VIRION; VIRUS STRAIN; ANIMAL; ANTIBODY SPECIFICITY; CHEMISTRY; CPG ISLAND; EMULSION; EPIDEMIC; FEMALE; GENETICS; IMMUNIZATION; IMMUNOLOGY;

MUS; ORTHOMYXOVIRIDAE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY SPECIFICITY; CPG ISLANDS; DISEASE OUTBREAKS; EMULSIONS; FEMALE; IMMUNITY, HUMORAL; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H5N1 SUBTYPE; MICE; NANOPARTICLES; OLIGODEOXYRIBONUCLEOTIDES; VACCINES, INACTIVATED;

EID: 77957906849     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012279     Document Type: Article

References (22)

1. World Health Organization (2010) Antigenic and genetic characteristics of influenza A(H5N1) and influenza A(H9N2) viruses and candidate vaccine viruses developed for potential use in human vaccines. Available: http://www.who.int/csr/disease/avian_influenza/guidelines/201002_H5_H9_VaccineVirusUpdate.pdf. Accessed 2010 Feb.
2. Hu AYC, Weng TC, Tseng YF, Chen YS, Wu CH, et al. (2008) Microcarrierbased MDCK cell culture system for the production of influenza H5N1 vaccines. Vaccine 26: 5736-5740.
3. Schubert C (2009) Boosting our best shot. Nat Med 15: 984-988.
4. Kistner O, Howard MK, Spruth M, Wodal W, Bruhl P, et al. (2007) Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25: 6028-6036.
5. Ninomiya A, Imai M, Tashiro M, Odagiri T (2007) Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine 25: 3554-3560.
6. Gupta RK (1998) Aluminum compounds as vaccine adjuvants. Adv Drug Del Rev 32: 155-172.
7. Cooper CL, Davis HL, Morris ML, Efler SM, Krieg AM, et al. (2004) Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 22: 3136-3143.
8. Weeratna RD, McCluskie MJ, Xu Y, Davis HL (2000) CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine 18: 1755-1762.
9. Baudner BC, Ronconi V, Casini D, Tortoli M, Kazzaz J, et al. (2009) MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020). Pharm Res 26: 1477-1485.
10. Singh M, Ott G, Kazzaz J, Ugozzoli M, Briones M, et al. (2001) Cationic microparticles are an effective delivery system for immune stimulatory CpG DNA. Pharm Res 18: 1476-1479.
11. Kovacs-Nolan J, Latimer L, Landi A, Jenssen H, Hancock REW, et al. (2009) The novel adjuvant combination of CpG ODN, indolicidin and polyphosphazene induces potent antibody- and cell-mediated immune responses in mice. Vaccine 27: 2055-2064.
12. Huang MH, Chou AH, Lien SP, Chen HW, Huang CY, et al. (2009) Formulation and immunological evaluation of novel vaccine delivery systems based on bioresorbable poly(ethylene glycol)-block-poly(lactide-co-e-caprolactone). J Biomed Mater Res B 90B: 832-841.
13. Huang MH, Huang CY, Lin SC, Chen JH, Ku CC, et al. (2009) Enhancement of potent antibody and T-cell responses by a single-dose, novel nanoemulsionformulated pandemic influenza vaccine. Microbes Infect 11: 654-660.
14. Huang MH, Huang CY, Lien SP, Siao SY, Chou AH, et al. (2009) Development of multi-phase emulsions based on bioresorbable polymers and oily adjuvant. Pharm Res 26: 1856-1862.
15. Garçon N, Goldman M (2009) Boosting vaccine power. Sci Am 301: 72-79.
16. Mosca F, Tritto E, Muzzi A, Monaci E, Bagnoli F, et al. (2008) Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci USA 105: 10501-10506.
17. Leroux-Roels I, Borkowski A, Vanwolleghem T, Dramé M, Clement F, et al. (2007) Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370: 580-589.
18. World Health Organization (2009) WHO recommendations on pandemic (H1N1) 2009 vaccines. Geneva: Pandemic (H1N1) briefing note 2. Available: http://www.who.int/csr/disease/swineflu/notes/h1n1_vaccine_20090713/en/. Accessed 2009 Jul 13.
19. Aucouturier J, Dupuis L, Deville S, Ascarateil S, Ganne V (2002) Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines 1: 111-118.
20. Newman MJ, Balusubramanian M, Todd CW (1998) Development of adjuvantactive nonionic block copolymers. Adv Drug Del Rev 32: 199-223.
21. Schultze V, D'Agosto V, Wack A, Novicki D, Zorn J, et al. (2008) Safety of MF59TM adjuvant. Vaccine 26: 3209-3222.
22. Del Giudice G, Fragapane E, Bugarini R, Hora M, Henriksson T, et al. (2006) Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene. Clin Vaccine Immunol 13: 1010-1013.